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Thirteen dogs with previously untreated multicentric lymphoma were enrolled in a prospective
study investigating the effects of low-dose rate total body irradiation (TBI) and chemotherapy. Dogs
received either 6 or 8 Gy TBI in half-body fractions, 2 weeks apart. Toxicity consisted of mild to moderate haematological and gastrointestinal (GI) signs. One dog died from treatment complications.
Anorexia was noted independent of dose. Haematological toxicity was more common and more
severe after 8 Gy treatment. GI toxicity was more likely postcaudal half-body irradiation with 8 Gy.
Other than leukotrichia, late effects from radiation were not observed. Results indicated that haematological and nonhaematological toxicity was dose dependent. However, the protocol was well
tolerated and treatment intensiﬁcation using a 2-week inter-radiation interval was possible in all
dogs treated with 6 Gy. Preliminary survival data for these dogs were very encouraging, providing
a strong rationale to analyse the efﬁcacy of low-dose rate irradiation (LDRI) in canine lymphoma.
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Currently, multidrug chemotherapy protocols
comprise the standard of care for canine lymphoma. Treatment initially results in high remission rates (up to 85%), but typically they are of
short duration (6–12 months).1 Patients almost
uniformly die from relapsing disease when neoplastic cells develop multidrug resistance (MDR).2,3
Thus, a need has arisen for complementary treatments to overcome MDR and to target cells within
lymphoma sanctuaries inaccessible to chemotherapy. Lymphoma requires systemic treatment and
apart from chemotherapy and immunotherapy
only wide-field irradiation (WFI), delivered as
either total body or sequential half-body treatments,
is capable of treating with systemic effect. Its
beneﬁt results from the exquisite radiosensitivity of

malignant lymphocytes and lack of cross-resistance
between chemotherapeutic drugs and radiation.2
In people with non-Hodgkin’s lymphoma, combined chemoradiation protocols have improved remission durations and survival times.3,4 WFI has also
been effective in canine lymphoma.5,6 However, doselimiting bone marrow (BM) and gastrointestinal (GI)
toxicities 5 require careful protocol design to limit
toxicity while maintaining efﬁcacy. Studies have evaluated the use of radiation alone 6 or in combination
with chemotherapy 7,8 and have used either total body
irradiation (TBI) with BM transplantation 9,10 or halfbody irradiation (HBI) without BM transplantation.7,8 WFI has been evaluated as a rescue protocol 11
and as consolidation of induction chemotherapy,7,9
but the most promising results have been obtained
by integrating HBI with induction chemotherapy.8

© 2008 University of Florida. Journal compilation © 2008 Blackwell Publishing Ltd

257

258

D. M. Lurie et al.

Current HBI protocols attempt to modulate toxicity
by manipulation of total dose administered, use of
split-dose delivery or varying the inter-radiation
treatment interval and/or eliminating the use of interradiation chemotherapy. These protocols have had
mixed results and there is no consensus as to the best
way to limit toxicity without compromising efﬁcacy.
The goal of this study was to determine the toxicity proﬁle of an intensiﬁed chemoradiation protocol, evaluating two dose levels (6 or 8 Gy) of
low-dose rate irradiation (LDRI) given as sequential half-body fractions 2 weeks apart. Our hypothesis was that LDRI would reduce toxicity to the
lungs, BM and GI tract allowing for a short interradiation interval and a therapeutic gain.

short-haired pointer, Golden retriever, German
shepherd, Irish setter, Labrador retriever and Tibetan
terrier); two neutered males and four neutered
females; median weight and age were 27.9 kg and
7.9 years, respectively. Group 2 consisted of seven
dogs (two Cocker spaniels, German shepherd, Golden
retriever, Pit bull, Bull mastiff and Rottweiller
cross); two males (one neutered) and five females
(four neutered); median weight and age were
29.9 kg and 7.9 years, respectively.
Tumour stages were as follows: group 1: 4a
(n = 4), 4b (n = 1) and 5b (n = 1); group 2, 3a (n = 1),
4a (n = 3), 4b (n = 2) and 5b (n = 1). Immunophenotype was: group 1, B-cell lymphoma (n = 6);
group 2, B-cell lymphoma (n = 6) and T-cell
lymphoma (n = 1).

Materials and methods
Treatment
Design
Dogs entered had stage 3, 4 or 5 multicentric lymphoma diagnosed by either cytological or histopathological evaluation of a lymph node. All dogs were
clinically staged (3–5) at diagnosis by using the World
Health Organization criteria for canine lymphoma.12
Staging included a complete blood count (CBC),
chemistry/electrolyte panel, urinalysis, thoracic
radiographs, abdominal ultrasound, BM aspirate
evaluation and tumour immunophenotype [CD3
(Serotec, Raleigh, NC, USA), Pan T-cell and CD79a
(Dako, Carpinteria, CA, USA), Pan B-cell] as previously described.13 Dogs were excluded if previously
treated for lymphoma or if they had any concomitant life-threatening disease. Dogs were randomized
to receive 6 Gy (group 1, n = 6) or 8 Gy (group 2,
n = 7) TBI interposed in a chemotherapy protocol for
canine lymphoma. Toxicity criteria for delaying
caudal HBI included: mean BM particle cellularity
£10%, absence of one or more BM cell lineages
(granulocytic, erythroid, or megakaryocytic),
neutropenia (<2500 L−1) or > 60% reduction in
neutrophil count from baseline value, thrombocytopenia (<100 000 L−1) or fever (>103.5).

Animals
Thirteen dogs were enrolled with the owners’
consent. Group 1 consisted of six dogs (German

All dogs were treated with a modiﬁed MadisonWisconsin protocol (Table 1).14 After one cycle of
induction chemotherapy, dogs received either
6 Gy (n = 6) or 8 Gy (n = 7) TBI calculated at the
midplane. Radiation was given in half-body
fractions at a 2-week interval with cranial and
caudal HBI scheduled for weeks 6 and 8, respectively. Anaesthesia was induced with PropoFlo
(Abbott Laboratories, North Chicago, IL, USA) and

Table 1. Chemoradiation treatment protocol: Following
week 12 repeat cycles of weeks 10–12 were administered at
2-week intervals until week 28. At week 28, doxorubicin
was substituted with actinomycin D (0.7 mg m−2).
Subsequent treatments were administered at 3-week
intervals until week 52 and then every 4 weeks until
discontinuing chemotherapy at week 104. Tx, treatment.
TX week
1
2
3
4
5
6
7
8
9
10
11
12

TX administered

Prescribed dose

L-asparaginase

400 IU kg−1
0.5 mg m−2
200 mg m−2
0.7 mg m−2
30 mg m−2

Vincristine
Cyclophosphamide
Vincristine
Doxorubicin
None
Cranial HBI
Vincristine
Caudal HBI
Vincristine
Cyclophosphamide
Vincristine
Doxorubicin

6 or 8 Gy
0.5 mg m−2
6 or 8 Gy
0.5 mg m−2
200 mg m−2
0.7 mg m−2
30 mg m−2
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maintained with isoﬂuorane (generic). LDRI
(8–14 cGy min−1) from a Clinac 4/80 (Varian
Medical Systems, Palo Alto, CA, USA) was given
through bilateral opposed portals at extended
source-to-skin distance (180–185 cm). Dogs were
placed in lateral recumbency, and cranial and
caudal ﬁelds were separated by a transverse line
drawn between the dorsal spinous process of the
13th thoracic vertebra and the xiphisternum as
previously described.15 These landmarks were used
to abut the cranial and caudal ﬁelds at the 50%
isodose line. All parts of the body were included
within the treatment ﬁeld allowing for at least a
2 cm beam fall-off at the edge of the patient. Bolus
material was not used and dose corrections for
tissue heterogeneity were not made. Source-toaxis distance dose calculations along the central
axis were performed using a computerized treatment planning system, Prowess 2000 (Small
Systems, Chico, CA, USA) into which hand
measurements of patient thickness and extended
source-to-skin distances were entered.

Radiation dosimetry
In vivo skin dose measurements were made on
entrance and exit surfaces with a dual diode dosimeter, Model 22D (CNMC Instruments; Nashville,
TN, USA). The diode was placed off central axis,
4 cm cranial or caudal from the line delineating
body halves, to ensure equivalent patient thickness
at both measurement points and eliminate shape as
a confounding factor. Skin dose was calculated by
adding entrance and exit doses in cranial versus
caudal locations and used to estimate the effects of
body size and tissue heterogeneity.

Assessment of radiation toxicity
All dogs were evaluated weekly during induction
and toxicity was graded according to VCOG guidelines;16 grades 1–5 being mild, moderate, severe, life
threatening and death, respectively. Haematological
toxicity (neutropenia or thrombocytopenia) grades
2–4 and GI toxicity (vomiting and diarrhoea)
grades 3 and 4 were considered dose limiting when
noted within the week following cranial and
caudal HBI.

Haematological toxicity was evaluated by CBCs
and cytological evaluation of BM aspirates. BM
samples were obtained from the humerus and
ilium 10–15 min before cranial and caudal HBI,
respectively. Samples were obtained from the humerus 2 weeks postcranial HBI and before caudal
HBI to evaluate BM recovery at that site. Samples
were obtained from the ilium 2 weeks postcaudal
HBI to evaluate BM recovery at that site. All BM
samples were reviewed post hoc by a single clinical
pathologist (M. M. F.). One slide from each sample
set was used to estimate overall cellularity and for a
200-cell differential count. Cellularity was estimated based on the proportion of unit particles
composed of haematopoietic cells (as opposed
to fat) and expressed as a mean percentage. The
differential count included categories for early erythroid (rubriblast through basophilic rubricyte),
late erythroid (polychromatophilic rubricyte through
metarubricyte), early granulocytic (myeloblast
through myelocyte), late granulocytic (metamyelocyte through mature granulocyte), monocyte/
macrophage, well-differentiated lymphocyte,
plasma cell and other (large cells of uncertain lineage, including those with morphology consistent
with poorly differentiated lymphocytes). Megakaryocyte numbers were estimated to be within
normal limits, increased or decreased, taking into
consideration the number of unit particles.
GI toxicity was evaluated by monitoring vomiting and diarrhoea and by faecal occult blood (FOB)
testing. Frequency and severity of vomiting diarrhoea and anorexia were monitored immediately
after and during the entire interval between
irradiation and subsequent chemotherapy for both
cranial and caudal halves. FOB testing was carried
out in all dogs receiving caudal HBI using standard
methods.17 Dogs were fed cottage cheese and rice
diet for 6 days, starting 3 days before irradiation to
obtain faecal specimens immediately before and
3 days post-irradiation. A positive test would only
be considered signiﬁcant in context of a negative
pre-irradiation result and full owner compliance in
feeding the prescribed diet.
Toxicity to the liver and kidneys was evaluated by
fasting and postprandial bile acid analysis precaudal
and 3 days postcaudal HBI and serum chemistry
analysis precaudal and 1-week postcaudal HBI.
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Statistical analysis

Treatment feasibility

Analysis of all continuous variables including
peripheral cell counts and constituent BM cell lineages
was carried out using two-way repeated measure
ANOVA to analyse the effects of inter-radiation
interval, radiation dose and BM sampling location.
All data were tested for deviance from normality
using Kolmogorov–Smirnov test. All post hoc pairwise comparisons of the mean responses of the
different groups were carried out by the Tukey’s test
for analysis. A paired t-test was used to analyse
differences in skin doses between the cranial and
caudal half body. Association between the skin dose
ratio of cranial to caudal HBI and body weight was
measured by the Pearson correlation coefﬁcient. All
computations were performed by use of statistical
software version 11.5 (SPSS, Chicago, IL, USA).
Statistical signiﬁcance was set for P < 0.05.

Four of six (group 1) and three of seven (group 2)
dogs received the planned treatment. Five dogs had
a 1-week treatment delay postcranial HBI. One dog
(group 1) died of progressive disease before caudal
HBI. Only three of ﬁve delays were associated with
deﬁned toxicity end-points. All three occurred in
group 2 and resulted from grade 3 neutropenia
(n = 1) and inadequate BM particle cellularity
(n = 2). One delay (group 1) was because of owner
concern with the lack of BM data and one (group 2)
because of an inability to return for the scheduled
caudal HBI. Two dogs in group 2 required hospitalization for supportive care, one with grade
3 neutropenia postcranial HBI and the other with
grade 4 vomiting and diarrhoea postcaudal HBI.
The latter was ultimately killed at the owner’s request. Although BM and other toxicity parameters
in the remaining dogs were not completely resolved
before caudal HBI, none of them developed any
complications requiring medical treatment. All 11
dogs that survived longer than 9 weeks were treated
with chemotherapy as scheduled in the protocol.

Analysis of outcome
The end-points evaluated were duration of remission
and survival times. Variables examined as indicators of prognosis included radiation dose, tumour
stage and substage (a or b), immunophenotype,
inter-radiation interval (2 or 3 weeks), remission
status after irradiation [complete remission (CR)
or not] and remission status during the overall
treatment (CR or not).
Correlations between prognostic variables were
analysed by use of the Pearson 2. Duration of response to treatment and survival time was computed
by use of the product-limit method. Progression-free
survival was used to analyse separately response duration in dogs that achieved CR and those that achieved
partial remission or had stable disease. Dogs were
censored if still alive at the time of analysis or if they
died for any reason (including treatment toxicity)
other than lymphoma. Actuarial estimates of survival
and progression-free survival distributions were tested
for statistical differences using log-rank statistics.

Results
The two groups were comparable with respect to
clinical characteristics, tumour stage/substage and
immunophenotype.

Haematological toxicity
CBC data from 2 weeks postcranial HBI showed
signiﬁcant decreases in the concentrations of neutrophils, lymphocytes, and platelets compared with
precranial HBI values (Table 2). No cytopenias were
noted in group 1 postcranial HBI but three of seven
group 2 dogs developed grade 1 thrombocytopenia,
one with concurrent grade 3 neutropenia (Table 3).
CBC data from 2 weeks postcaudal HBI showed
signiﬁcant decreases in the concentrations of neutrophils, lymphocytes and platelets compared with
baseline precranial HBI values, but no signiﬁcant
decreases in any blood cell counts compared with
precaudal HBI treatment values (Table 2). Three of
ﬁve group 1 dogs developed grade 1 thrombocytopenia postcaudal HBI. In group 2, ﬁve of seven
dogs developed grade 1 thrombocytopenia, three
with concurrent neutropenia (1, grade 3; 1, grade 2
and 1, grade 1). A sixth dog developed grade 1 neutropenia without thrombocytopenia. The seventh
dog was killed before obtaining a postcaudal HBI
CBC (Table 3).
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Table 2. Periradiation CBC analysis: CBC evaluation; median (range) pre-Cr HBI, 2 weeks post-Cr HBI/pre-Cd HBI and

2 weeks post-Cd HBI

Pre-Cr HBI
6 Gy
8 Gy
Pre-Cd HBIa
6 Gy
8 Gy
Post-Cd HBIb
6 Gy
8 Gy
Normal range

Neutrophils L−1

Lymphocytes L−1

Platelets 103 L−1

8633 (3894–10061)
10004 (6225–16910)

1131 (97–1534)
760 (348–1797)

483 (450–784)
392 (279–757)

3814 (2550–4836)
3555 (945–7425)

736 (544–825)
450 (270–828)

269 (237–396)
223 (120–321)

3713 (2808–8130)
1897 (924–4558)
3000–15 000

507 (432–612)
384 (79–650)
1000–4000

162 (132–304)
114 (104–228)
150–400

Cr HBI, cranial half-body irradiation; Cd HBI, caudal half-body irradiation.
a
(All values) P < 0.001 compared with pre-Cr HBI.
b
(All values) P < 0.001 compared with pre-Cr HBI.

Comparison of cranial BM samples before versus after cranial HBI revealed signiﬁcant ﬁndings
that were independent of the radiation dose (Table 4).
The postcranial HBI sample had a decreased ratio
of granulocytic to erythroid cells (0.37) compared
with the precranial HBI value (1.46). Megakaryocytes were interpreted to be decreased in 4 of 13
dogs (two from each group) postcranial HBI. The
estimated cellularity of the caudal BM sample
collected 2 weeks postcranial HBI was signiﬁcantly
higher than the cranial BM sample collected at the
same time (60 versus 38%, respectively). No significant differences in the proportions of different cell
types were detected between these two samples.
Comparison of caudal BM samples before versus
after caudal HBI revealed signiﬁcant ﬁndings that

were independent of the inter-radiation interval
(2 or 3 weeks) and radiation dose (Table 5). The
postcaudal HBI sample had a decreased ratio of
granulocytic to erythroid cells (0.3) compared with
the precaudal HBI value (1.0). Megakaryocytes were
interpreted to be decreased in 9 of 12 dogs postcaudal HBI (three in group 1 and six in group 2).

Nonhaematological toxicity
Gastrointestinal
No dog vomited immediately (0–2 h) postcranial
HBI or at home in the interval between irradiation
and subsequent chemotherapy. One of ﬁve (group 1)
and four of seven (group two) dogs experienced

Table 3. Treatment toxicity (VCOG guidelines)
Grade
Toxicity

1

Grade
2

3

4

5

6 Gy (n = 6)
Postcranial HBI
Neutropenia
Thrombocytopenia

—
—

—
—

—
3
1
—
1
—

—
—
—
—
1
4

2

3

4

5

—
—

1
—

—
—

—
—

1
—
—
—
2
4

1
—
1
—
4
1

—
—
1
1
—
1

—
—
—
—
—
—

8 Gy (n = 7)
—
—

—
—

—
—

6 Gy (n = 5)
Postcaudal HBI
Neutropenia
Thrombocytopenia
Vomiting
Diarrhoea
Anorexia
Lethargy

1

—
3
8 Gy (n = 7)

—
—
—
—
3
1

—
—
—
—
—
—

—
—
—
—
—
—

2
5
2
—
1
1
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Table 4. Comparison of cranial BM samples before and

after cranial HBI

Particle cellularity (%)
Early granulocytic (%)
Late granulocytic (%)
Early erythroid (%)
Late erythroid (%)

Precranial HBI

Postcranial HBI

40
7
50
10
29

38
7
18a
16a
52a

a

Signiﬁcant difference from pre-HBI value.

grade 1 vomiting immediately postcaudal HBI. Of
these ﬁve dogs, zero of one (group 1) and two of
four (group 2) continued to vomit at home. One
dog experienced grade 3 and the other grade 4
vomiting. Diarrhoea (grade 4) manifested in 1 of
13 dogs and was in the same dog with grade 4 vomiting postcaudal HBI.
Anorexia was noted uniformly postcaudal HBI.
In group 1, anorexia was categorized as grade 3
(n = 3), grade 2 (n = 1) and grade 1 (n = 1), while in
group 2, it was grade 3 (n = 4), grade 2 (n = 2) and
grade 1 (n = 1).
Twelve of 13 dogs had negative FOB tests
precaudal HBI. Two of 13 dogs had positive FOB
tests postcaudal HBI, 1 of which was positive
before irradiation and the other had been fed a
meat-based diet before testing.
Kidney and liver
No dog showed any signiﬁcant serum biochemistry
abnormalities including preprandial and postprandial bile acids.
Skin

determined. Changes likely to be associated with
radiation exposure included diffuse cranial halfbody leukotrichia (Fig. 1) in 2 of 11 dogs, 1 in each
group. Two of 11 dogs had diffuse greying of the
coat affecting both body halves. Two of 11 dogs
experienced patchy alopecia, which resolved
despite continued chemotherapy and 2 of 11 experienced patchy alopecia, which did not resolve
during ongoing chemotherapy (104 weeks).
Dosimetry
The measured skin dose of the cranial half body
was signiﬁcantly higher than the caudal half body
(P < 0.001). The average (±SEM) skin dose ratio
(cranial:caudal) was 1.15 (±0.03). The higher skin
dose for cranial versus caudal halves reﬂects the
increased transmission of radiation through lung
tissue. No signiﬁcant association was found between increased dose to the cranial half body and
body weight.
Outcome
The median follow-up time to last contact or death
was 850 days. All dogs were available for remission
and survival analysis. A negative correlation was
found between radiation dose and substage
(P = 0.033), and positive correlations were found
between stage and substage (P = 0.009) and
between achieving CR and remission status before
irradiation (P = 0.001).
The median remission duration was 1126 days
(SE, 287 days) and the median survival time was
1131 days (SE, 391 days). Univariate analysis of

Eight dogs had coat changes. The speciﬁc contribution of irradiation and chemotherapy could not be
Table 5. Comparison of caudal BM samples before and

after caudal HBI

Particle cellularity (%)
Early granulocytic (%)
Late granulocytic (%)
Early erythroid (%)
Late erythroid (%)
a

Precaudal HBI

Postcaudal HBI

60
8
37
12
33

19a
3a
16a
13
51

Signiﬁcant difference from pre-HBI value.

Figure 1. Radiation ﬁeld-associated leukotrichia.
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progression-free survival revealed that remission
status after completion of irradiation protocol was
signiﬁcantly associated with duration of response
and prognosis (P = 0.03) (Fig. 2). In dogs that were
in CR before irradiation, the 1-year and 3-year
progression-free survival rates were 89 (SE, 10.4%)
and 64% (SE, 16.9%). Although median survival
times were longer in dogs that were in CR before
irradiation (median not reached) than in dogs that
were not in CR (median 93 days), the difference in
survival distribution was not statistically signiﬁcant
(P = 0.08) (Fig. 3). None of the other variables evaluated was found to affect remission or survival.
However, these ﬁndings should be interpreted
cautiously because of the low statistical power
because of the small sample size.

Discussion
This LDRI protocol attempted to enhance the therapeutic gain of a combined chemoradiation protocol by shortening the inter-radiation interval.
Classically, decreased tissue toxicity associated with
LDRI results from the repair of sublethal damage
that occurs during prolonged radiation exposure.18
We hypothesized that LDRI would decrease normal tissue toxicity and increase the therapeutic
index by minimizing tumour cell repopulation
during a shortened inter-radiation interval. A dose
rate of 8–14 cGy min−1 was selected based on
previously published data.17,18 This resulted in
treatment times ranging between 60 and 80 min. A

Figure 2. Progression-free survival rate: comparison of
dogs in CR versus PR or SD postcaudal HBI. CR, complete
remission; PR, partial remission; SD, stable disease
(P = 0.03).

Figure 3. Survival rate: comparison of dogs in CR versus
PR or SD postcaudal HBI. PR, partial remission; SD, stable
disease (P = 0.08).

lower dose rate was considered but would have
resulted in signiﬁcantly prolonged treatment time
and increased anaesthesia costs thought to be
impractical.
Decreases in the concentrations of circulating
neutrophils, platelets and lymphocytes were evident postcranial HBI and persisted postcaudal
HBI; however, dose-limiting cytopenias were rare
and only occurred in group 2. Cytopenias were
more common postcaudal HBI in both groups but
were more frequent and severe in group 2. Our
assumption is that cytopenias were a direct result
of radiation-induced damage to BM haematopoietic elements and impaired granulopoiesis and
thrombopoiesis. The increased frequency postcaudal HBI most likely reﬂects the fact that caudal HBI
always followed cranial HBI resulting in diminished
BM stores with which to replenish cell populations.
With respect to severity, haematological ﬁndings
were consistent with those of other investigators
7,8,19
where fractionation and/or prolonged intertreatment intervals were used.
The effect of dose rate versus fractionation has
been evaluated in dogs.5,17 LDRI resulted in the
best therapeutic ratio of inactivation of haematopoietic precursor cells to acute toxicity. While
inactivation and recovery of precursor cells was not
dose rate dependent, the nadirs of leucocyte,
lymphocyte and platelet counts were lower in dogs
treated at higher dose rates.5 Additionally, it was
shown that a single dose of TBI administered at
60 cGy min−1 versus 10 cGy min−1 was more BM
toxic as indicated by more profound nadirs in
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peripheral blood counts.19 This result agreed with a
number of previous studies showing greater organ
toxicity with higher dose rates.18,19 In dogs, toxicity
to the lymphoid system increases signiﬁcantly
when dose rate is increased by 1 log.20
BM cells represent the most radiosensitive
mammalian cells.18 In vitro experiments have
demonstrated that BM has virtually no capacity for
repair.18 However, it has been demonstrated that
only 10% of the body’s BM needs to be spared to
allow the otherwise lethally irradiated portion to be
repopulated.21 Repopulation may occur as a result
of surviving stem cells within the irradiated
BM compartment or through migration of stem
cells from the unexposed BM compartment.22,23
Humerus BM particle cellularity ³10% was set as
our threshold for the administration of caudal HBI,
although in most instances cellularity exceeded this
value. Only two dogs had treatment delay because
of inadequate BM cellularity. BM toxicity of fractionated versus single-dose TBI has been shown to
be identical when single doses are administered at
an LDR (10 cGy min−1).24 As dose rate is lowered
and treatment time is lengthened, greater cellular
recovery (because of repair or repopulation) of
radiation damage occurs during exposure.18 This
results in decreased toxicity to BM, lungs and GI
organs.21,23 We predict the resultant decrease in
inter-radiation interval will outweigh any sparing
effect of LDRI on lymphoid tissue resulting in an
overall therapeutic gain.
The lack of difference in estimated cellularity of
humerus BM samples before and after cranial HBI
was an unexpected ﬁnding, especially in light of the
CBC ﬁndings. The most likely explanation for this
is that there was decreased cellularity, mostly
because of decreased granulopoeisis, in the cranial marrow compartment postcranial HBI, but we
failed to detect it because of the limitations of aspiration cytology (core biopsy and histopathology is
more reliable,25 but was not carried out).
The estimated cellularity of the caudal BM samples before caudal HBI was signiﬁcantly higher
than the cellularity of the cranial samples before
cranial HBI. Although this may indicate compensatory hyperplasia in the caudal compartment after
cranial HBI, the study design did not allow us
to test this hypothesis. It is also possible that we

underestimated the cellularity of the cranial BM
samples before HBI, which may explain why no
apparent difference in the cellularity of cranial BM
samples before and after cranial HBI was noted.
Although the changes were not statistically
signiﬁcant, neutrophil, lymphocyte and platelet
counts all decreased in both treatment groups
following caudal HBI, consistent with the signiﬁcant decrease in estimated cellularity of caudal BM
samples obtained precaudal and postcaudal HBI.
Compensatory hyperplasia in the cranial compartment after caudal HBI may have prevented a more
dramatic decrease in peripheral cell counts, but
direct evidence of this is lacking.
The lower proportions of granulocytic cells in
BM samples post-HBI compared with pre-HBI,
and the lack of a similar pattern in the erythroid
lineage, suggests that the granulocytic lineage was
more susceptible than the erythroid lineage to
radiation-induced damage. Researchers have shown
that in people, radiation does not signiﬁcantly alter
the function or longevity of mature erythrocytes
and nucleated erythroid precursors appear more
radiation resistant than granulocytic precursors.26
Our data suggest that the canine erythroid lineage
is also more resistant than the granulocytic lineage
to the effects of ionizing radiation.
In this study, thrombocytopenia and decreased
megakaryocyte numbers were more common postcaudal HBI but was mild in both groups. In people,
thrombocyte lifespan is only 8–9 days in peripheral
blood, but the levels are not immediately affected
by ionizing radiation because of a protracted megakaryocyte response. Only the earliest progenitors
undergo immediate lethal changes. Most of the
remaining megakaryocytes, although damaged,
will continue some degree of maturation and some
will be capable of limited platelet production. This
provides a slowly diminishing source of platelets.26
Acute toxicity of TBI other than diminished
haematopoiesis is primarily GI. The progression of
the GI syndrome post-irradiation is characterized
by anorexia, abdominal cramping, vomiting, diarrhoea, lethargy, dehydration and infection.26 In
this study, GI signs were much more likely after
caudal HBI, which likely reﬂects that no signiﬁcant
portion of the GI tract was included within the
cranial half-body ﬁeld. We speculate that vomiting
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immediately after caudal HBI was likely a serotoninmediated event because of direct action of ionizing
radiation on enterochromafﬁn cells of the GI
lining.27 The acuteness of onset is consistent with
the prodromal stage of GI syndrome. The two dogs
that continued to vomit at home may still have
been exhibiting signs of the prodromal stage,
bordering on the latent stage of GI syndrome at
which point cells lining the GI tract are dying.28
Apart from anorexia, very little GI toxicity (vomiting or diarrhoea) was noted in this study, but was
more common in group 2. Anorexia, starting
within 1–2 days postcaudal HBI was likely associated with the prodromal stage. We speculate that
prolonged anorexia, 8–10 days post-irradiation was
likely associated with general malaise secondary to
myelosuppression. No dog showed evidence of GI
ulceration as evaluated by FOB testing. In dogs,
LDRI has been signiﬁcantly associated with
increased treatment tolerance with respect to GI
toxicity.5,28 Kidney and liver toxicity were not
clinically relevant issues in this study.
Field-related alopecia has been reported in dogs
undergoing WFI.8 In this study, radiation-related
leukotrichia was seen in two dogs. Increased skin
surface dose measured in the cranial half body
most likely reﬂects a greater transmission of radiation through less dense air-ﬁlled lung. Clinical
evidence of lung toxicity (pneumonitis and/or
ﬁbrosis) was not observed in this study but may
have occurred at a subclinical level. Although this
study mostly evaluated acute toxicity, long-term
follow-up in all dogs was available as all dogs
returned for follow-up chemotherapy until completion of the protocol at 2 years or death. During
the entire evaluation period, no dog showed any
evidence of clinically signiﬁcant kidney, liver, lung
or BM late effects.
Current TBI protocols involve sequential HBI
with either 8 Gy (two consecutive 4 Gy fractions
24 h apart) 7,8,29 or 6 Gy (single fraction) 29 with a
3- to 4-week inter-radiation interval. These protocols use high dose rate irradiation and presumably
rely on prolonged inter-radiation intervals to avoid
signiﬁcant toxicity. While successful in limiting
toxicity, these protocols have not resulted in a signiﬁcant improvement in survival.7,8 This is most
likely because of the rapid doubling time (28–32 h)

of lymphoma cells 30,31 and subsequent repopulation of the irradiated half body by cells mobilized
from nonirradiated tissues. Our study attempted
to minimize tumour repopulation by shortening
the inter-radiation interval to 2 weeks and by
administering chemotherapy in between radiation
doses. The vincristine dose (weeks 7 and 9) was
decreased as a precautionary measure to minimize
the risk of severe BM toxicity following irradiation.
Our results suggest that this protocol allows for the
maximal beneﬁt of combined chemoradiotherapy,
although it should be noted that high dose rate protocols with 2-week inter-radiation intervals have not
been directly evaluated and may also be feasible.
As with most cancer therapies, it has been shown
that the initial performance status of patients
treated with HBI is one of the strongest determinants of outcome.32 Patients with more complete
initial responses ultimately have longer overall
median survival times.33 This was consistent with
our results as two of three dogs that did not achieve
CR postcaudal HBI died within 153 days, whereas
the third dog had an indolent form of the disease
associated with improved survival. In this study,
radiation was performed at weeks 6 and 8, respectively, as most patients on multidrug protocols will
have achieved CR by this time. No beneﬁt could be
seen to waiting any longer before initiating the
respective HBI treatments. We also speculated that
a relatively fresh BM would be more likely to
recover from radiation exposure than marrow
that had received multiple insults from previous
chemotherapy exposures.
Our results show that this LDRI protocol was
generally well tolerated in dogs treated with 6 Gy.
Treatment intensiﬁcation using a short 2-week
inter-radiation interval was possible in all dogs
treated with 6 Gy. Our preliminary data suggest
that signiﬁcant improvements in ﬁrst remission
duration and survival time can be obtained with
combination treatment protocols. One important
limitation of this study is the small number of
patients evaluated especially in light of several
treatment delays that occurred. Currently, a larger
clinical trial is underway to evaluate the efﬁcacy of
this protocol. Another aspect to evaluate is whether
or not inter-radiation vincristine is beneﬁcial or if
it contributes to radiation treatment delays.
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